2 promising penny stocks to buy on the dip

As stock markets continue to correct, I am hunting for oversold penny stocks that I think could help turbocharge my portfolio returns without breaking the bank.

| More on:
Female florist with Down's syndrome working in small business

Image source: Getty Images

For those who are willing to stomach the volatility, penny stocks offer an exciting opportunity to get in on the ground floor of tomorrow’s successful businesses.

Here are two that could be a good fit for my portfolio:

Red Cat Holdings

This Puerto Rico-based company produces drone products, technologies and services.

Over the last decade, drones have become increasingly noticeable at parks, on beaches and in other open-space areas.

Aside from the hobbyist drone market, the technology is also being adopted in a range of industries, from videography to weather monitoring, firefighting and even delivery services.

Red Cat Holdings (NASDAQ:RCAT) offers investors a chance to get a piece of the drone market, valued at $100bn in 2020 and growing at 20.5% annually.

Most eye-catching is the company’s ‘drone box’ technology, which is the equivalent of the ‘black box’ on an aeroplane. By tracking drone flight data, the technology allows operators in this nascent sector to comply with growing regulatory demands and more easily qualify for drone insurance. 

Then there is Rotor Riot, which is Red Cat Holding’s retail and media arm, which pumps out slick YouTube videos for its 200,000 subscribers, driving customers to its online drone store, rotorriot.com.

Red Cat Holdings is a tiny fish in this sector, and its lunch could end up being eaten by behemoths like Chinese drone manufacturers DJI or Yuneec.

But with year-on-year revenue growth in the most recent quarter up over 300%, from $428,000 to $1.9m, Red Cat Holdings is so far gobbling up market share in this booming sector.

Trading at $2, down over 8% year to date, I would be happy to buy the dip on Red Cat Holdings, which is priced at a reasonable multiple of 12 times trailing sales.

Clovis Oncology 

This small-cap pharmaceutical company based in Colorado has seen its stock price rally by over 100% in June, from $0.66 to $1.49, following the publication of positive interim phase 1/2 clinical trial results for one of its patented drugs.

Still, plucky investors can talk about ‘buying the dip’ on Clovis Oncology (NASDAQ:CLVS), as the risk-off sentiment triggered by rising interest rates and high inflation has the company’s share price trading at a 48% discount compared with the beginning of 2022.

Clovis Oncology has two main products:

  • Rucaparib, sold under the brand name Rubraca, is a pill for certain types of ovarian and prostate cancers that has been approved for use in the UK, the EU and the US.
  • FAP-2286, a radioactive substance that attaches itself to solid tumours for imaging and therapeutic purposes. FAP-2286 has not been approved for use anywhere yet.

On 14 June, Clovis Oncology reported positive results from its phase 1 trial of FAP-2286, leading to a massive jump in its share price.

Further news from the company’s trial of FAP-2286 will likely cause similarly large swings in the price – and new investors could be left with startling losses if the drug’s efficacy is called into question by unfavourable findings.

So far, however, the trial is going well and none of the nine patients given FAP-2286 for solid tumours have had to abandon or cut back their dosage due to side effects, while one of the patients has exhibited a partial response to the radiotherapy drug.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be considered so you should consider taking independent financial advice.

Mark Tovey does not have a position in any of the companies mentioned. The Motley Fool UK has no position in any of the shares mentioned. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Female analyst sat at desk looking at pie charts on paper
Investing Articles

Is now the time to be snapping up Rolls-Royce shares?

Rolls-Royce shares have faced numerous setbacks in the recent past. However, could now be the time to buy? This Fool…

Read more »

Investing Articles

Here’s why GSK and Haleon shares have tanked this week

Shares in both GSK and its spin-off Haleon have plummeted this week. Edward Sheldon looks at what's going on and…

Read more »

Playful senior couple in aprons dancing and smiling while preparing healthy dinner at home
Investing Articles

My Aviva shares leapt 17%. Should I sell or buy more?

Aviva shares have soared by a sixth since I bought them in late July. Should I sell after this sudden…

Read more »

Mindful young woman breathing out with closed eyes, calming down in stressful situation, working on computer in modern kitchen.
Investing Articles

Lloyds shares are down 20% since January. Should I sell or buy more?

Lloyds shares have fallen by almost a fifth since their 2022 peak of 56p in January. Having bought some at…

Read more »

Man changing battery on electric bicycle
Investing Articles

Is Elon Musk on the money about lithium shares?

With Elon Musk calling lithium mining a “license to print money”, should I be buying lithium shares now – or…

Read more »

Serious puzzled businessman looking at laptop
Investing Articles

Will Arrival stock hit $2 anytime soon?

Arrival stock has lost 80% of its value this year. With start of production imminent, can it stage a recovery…

Read more »

Smiling young man sitting in cafe and checking messages, with his laptop in front of him.
Investing Articles

A top UK value stock to buy from the FTSE 250!

Stock market weakness has left many quality shares looking ultra cheap. I'm on the hunt for UK value stocks and…

Read more »

Elevated view over city of London skyline
Investing Articles

Can the tempting M&G dividend yield of 8%+ last?

The M&G dividend has increased again this week. But will it last in a challenging economic environment -- and should…

Read more »